Nombre del producto:4-bromo-6-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile

IUPAC Name:4-bromo-6-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile

CAS:2068065-05-2
Fórmula molecular:C8H4BrN3O
Pureza:95%+
Número de catálogo:CM325559
Peso molecular:238.04

Unidad de embalaje Stock disponible Precio($) Cantidad
CM325559-100mg in stock ƥŪ
CM325559-250mg in stock Ūƥȯ
CM325559-1g in stock ȯƥƿ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :2068065-05-2
Fórmula molecular:C8H4BrN3O
Punto de fusión:-
Código de sonrisas:N#CC1=C2C(Br)=CC(O)=CN2N=C1
Densidad:
Número de catálogo:CM325559
Peso molecular:238.04
Punto de ebullición:
Nº Mdl:
Almacenamiento:

Category Infos

Pyrazolopyridines
Over the past few years, many pyrazole fused-ring systems, especially with applications in medicinal chemistry, have been published. These include general structures such as pyrazoline, pyrazoline, pyrazoquinoline, pyrazoloisoquinoline, pyrazoline, pyrazolopyrazine, pyrazolopyrazine, pyranopyrazole, pyrano Pyrazoles, pyrazolotriazines and pyrazole fused phosphorus rings.

Column Infos

Selpercatinib
The FDA has granted accelerated approval to selpercatinib (Retevmo; Eli Lilly and Company) for pediatric patients aged 2 years and older with RET-altered metastatic thyroid cancer or solid tumors, the federal agency announced in a press release. Selpercatinib is a highly selective, potent RET inhibitor. It works by blocking a type of enzyme (kinase) and helps prevent the cancer cells from growing.

Related Products